When did Inhibrx Biosciences, Inc. report Q4 2024 earnings?

Inhibrx Biosciences, Inc. (INBX) reported Q4 2024 earnings on March 17, 2025 before market open.

What were Inhibrx Biosciences, Inc.'s Q4 2024 revenue and EPS?

Inhibrx Biosciences, Inc. reported revenue of $100.0K and diluted EPS of $-3.09 for Q4 2024.

Did Inhibrx Biosciences, Inc. beat estimates in Q4 2024?

EPS missed the consensus estimate of $-2.88 by $0.21.

Where can I find Inhibrx Biosciences, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0002007919-25-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.

Inhibrx Biosciences, Inc. INBX Q4 2024 Annual earnings

Reported March 17, 2025 · Before market open

Revenue$100.0K Diluted EPS-$3.09Miss by $0.21

EPS estimate-$2.88

Next report

Aug 12, 2026 (in a month)

EPS estimate-$2.28

Financials

Q4 2024

Income statement

See full

Revenue$100.0K-93.9%

Operating income-$49.9M+43.4%

Net income-+100%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$152.6M-45.1%

Total debt$8.0M-96.2%

Total equity$133.6M+207%

Total assets$180.8M-41.3%

Cash flow

See full

Operating cash flow-$43.7M+23.1%

CapEx$16.0K-99.5%

Free cash flow-$43.7M+27.4%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$222.93M-59.5%

Enterprise value$78.38M-83.7%

P/E0.1×—

P/S1,114.6×+809×

Profitability

See full

Operating margin-165,724%-180,001pp

Net margin867,718.5%+854,712pp

FCF margin-98,503%—

Returns & leverage

See full

Return on equity1,960%+1,640pp

Debt / equity0.1×-4.8×

Current ratio3.9×-1.3×

Versus estimates

Revenue

Q2 2025$1.3M

Q4 2024$100.0K

Diluted EPS

Q1 2026-$2.15Beat by $0.22 Q4 2025-$2.11Miss by $0.03 Q3 2025-$2.28Miss by $0.20 Q2 2025-$1.85Beat by $1.07 Q1 2025-$2.80Miss by $0.25

Q4 2024-$3.09Miss by $0.21

Ask the moment Inhibrx Biosciences, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Inhibrx Biosciences, Inc. report Q4 2024 earnings?: Inhibrx Biosciences, Inc. (INBX) reported Q4 2024 earnings on March 17, 2025 before market open.
What were Inhibrx Biosciences, Inc.'s Q4 2024 revenue and EPS?: Inhibrx Biosciences, Inc. reported revenue of $100.0K and diluted EPS of $-3.09 for Q4 2024.
Did Inhibrx Biosciences, Inc. beat estimates in Q4 2024?: EPS missed the consensus estimate of $-2.88 by $0.21.
Where can I find Inhibrx Biosciences, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0002007919-25-000019) directly on SEC EDGAR. The filing index links above go to sec.gov.